Sept 14 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP CLINICAL DEVELOPMENT UPDATE FOR ITS FIRST-IN-CLASS LAG-3 ANTIGEN PRESENTING CELL ACTIVATOR CANDIDATE EFTILAGIMOD ALPHA
- IMMUTEP LTD - NEW AND IMPORTANT CLINICAL DATA IN 1L NSCLC EXPECTED IN Q4 2022
- IMMUTEP LTD - PLANNING AND REGULATORY INTERACTIONS ONGOING WITH A FOCUS NOW PRIORITISING 1(ST) LINE (1L) NSCLC
- IMMUTEP LTD - CONTINUED EXPANSION OF EFTI IN ADDITIONAL INDICATIONS AND COMBINATIONS PLANNED
- IMMUTEP LTD - STRONG BALANCE SHEET PROVIDES CASH RUNWAY INTO EARLY 2024
News: IMM Immutep Provides Clinical Development Update For Its First-In-Class LAG-3 Antigen...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.005(2.00%) |
Mkt cap ! $366.9M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 24.5¢ | $17.23K | 69.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 172737 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 99846 | 14 |
View Market Depth
| Last trade - 10.19am 17/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |